Platelet activation in psoriasis.
Recent epidemiological studies have suggested that psoriasis represents a risk factor for thrombotic vascular diseases. In order to evaluate the possible role of hemostatic changes in the development of thrombotic episodes in psoriasis, some parameters of the hemostatic "balance" were investigated in 22 male psoriatic patients and compared to those of 22 male control subjects. Incidence of known risk factors for vascular diseases (diabetes, hypertension, smoking, dyslipidemia) was comparable in the two study groups. There were no statistically significant differences in platelet count, circulating platelet aggregates, platelet production of malondialdehyde (MDA), total plasma antithrombin and fibrinolytic activities. In patients with psoriasis the incidence of spontaneous platelet hyperaggregability and plasma levels of beta-thromboglobulin were significantly higher than in control subjects. Platelet regeneration time, measured as MDA recovery after aspirin ingestion, was significantly shorter in psoriatic patients. These data suggest that an in vivo platelet activation occurs in patients with psoriasis and could contribute to the development of thrombotic complications. The release of mitogenic and inflammatory substances by activated platelets may play a role in the histogenesis of psoriatic lesions.
Berrettini
M
M
Parise
P
P
Constantini
V
V
Grasselli
S
S
Nenci
G G
GG
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000502:physiology*; D006487:Hemostasis; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D010974:Platelet Aggregation; D011565:Psoriasis / Q000097:blood* / Q000150:complications; D012306:Risk; D013927:Thrombosis / Q000209:etiology; D001620:beta-Thromboglobulin / Q000378:metabolism
D001620:beta-Thromboglobulin; D008315:Malondialdehyde